-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$3.0041.51% Upside
Mersana Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Mersana Therapeutics, Inc.?
Mersana Therapeutics, Inc. has been rated by research analysts at Robert W. Baird in the past 90 days.